Skip to main content

Table 2 OS, PFS, and RR in patients with EGFR Mut + NSCLC

From: Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

 

n

Overall survival

Progression-free survival

Response rate

 

Median

(months)

95% CI

Median

(months)

95% CI

n

%

Overall

320

17.2

15.1–19.8

9.1

8.5–10.3

163

50.9

Gender

 Female

200

20.4

17.2–23.8

10.3

9.4–12.6

110

55.0

 Male

120

12.2

9.6–17.0

6.8

5.1–8.8

53

44.2

  

P < 0.001a

 

P < 0.001a

  

P = 0.078b

Histology

 Adenocarcinoma

286

17.0

15.1–19.5

9.3

8.7–10.5

148

51.7

 Non-adenocarcinoma

33

18.4

12.2–NA

6.9

5.1–21.3

15

45.5

    

P = 0.82a

  

P = 0.616b

Smoking habit

 Ever smoker

168

15.1

13.6–18.1

8.1

6.8–10.3

79

47.0

 Never smoker

150

20.4

17.0–26.5

10.2

9.1–12.0

83

55.3

  

P = 0.014a

 

P = 0.029a

  

P = 0.172b

First-line therapy

 Ever EGFR inhibitor

220

16.4

14.3–20.3

9.6

8.8–11.1

118

53.6

 No EGFR inhibitor

100

18.1

15.1–23.5

8.7

6.3–11.2

45

45.0

 Ever gefitinib

206

16.4

14.2–20.4

9.6

8.6–10.9

111

53.9

 TKI

188

17.4

14.7–20.4

9.7

8.5–11.4

100

53.2

 Gefitinib

176

17.4

14.7–20.4

9.6

8.1–11.3

94

53.4

 Chemotherapy

100

18.1

15.1–23.5

8.7c

6.3–11.2

45

45.0

 Chemotherapy → TKI

32

13.9

9.1–NA

9.2

8.6–21.6

18

56.3

 Chemotherapy → gefitinib

30

10.3

8.6–21.6

13.8

8.6–NA

17

56.7

 TKI maintenance planned

57

19.8

15.0–NA

10.3

8.7–16.3

38

66.7

 No TKI maintenance planned

263

16.4

14.2–19.1

9.0

7.7–10.3

125

47.5

 TKI from start

158

16.4

13.1–20.3

9.7

7.6–11.4

  

 Change to TKI/planned TKI maintenance

76

17.9

14.8–NA

10.0

8.7–14.8

  

 No TKI

86

18.0

14.2–22.5

8.1

6.1–11.2

  

TKI treatmentd, e

 TKI from start

188

17.4

14.7–20.4

9.7

8.5–11.4

  

 TKI switch/planned maintenance

46

17.0

10.0–NA

10.0

8.6–21.4

  

 No TKI (first + maintenance)

86

18.0

14.2–22.5

8.1

6.1–11.2

  

 TKI documented

229

17.9

15.0–20.5

10.1

8.9–11.7

  

 Gefitinib documented

206

17.4

14.8–20.4

10.0

8.8–11.4

  

 Planned TKI documented

12

NA

NA

8.7

3.6–NA

  

 No TKI documented

79

15.4

13.8–22.5

7.0

5.1–9.4

  

TKI treatmente, f

 TKI documented

242

18.4

16.3–21.8

    

 Gefitinib documented

213

18.1

15.5–21.4

    

 Planned TKI documented

17

17.0

10.0–NA

    

 No TKI documented

61

13.6

9.3–15.4

    

EGFR mutation

 TKI-sensitive

231

18.1

15.5–20.9

10.2

9.1–11.7

132

57.1

 TKI-insensitive

24

17.9

6.9–NA

5.4

4.0–9.4

8

33.3

       

P = 0.044b

  1. OS, PFS, and RR by demographic and clinico-pathological characteristics, and therapy in patients with EGFR Mut + NSCLC. aLog-rank test. bChi-squared test. cIncludes two patients in whom the therapeutic agent was changed within first-line treatment but the new agent was not documented. dTKI until first documented tumor progression. eAnalysis not prespecified. fPatients who ever received a TKI as part of their complete therapy course
  2. CI, confidence interval; NA, not available; NSCLC, non-small-cell lung cancer; RR, response rate; OS, overall survival; PFS, progression-free survival; TKI, tyrosine kinase inhibitor
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us